Thursday 7 May, 2026
Objectives Pharmacometric or population modelling traditionally relies on individual level data. Increasingly, previously published models and summary data are recognized…
Read morePoster: Methodology - New Modelling Approaches
The Empirical Bayes Variational Autoencoder – A Neural ODE Approach for Population Modeling in Pharmacology
Thursday 7 May, 2026
Objectives Population modeling using nonlinear mixed-effects (NLME) frameworks is fundamental to pharmacometrics, enabling rigorous quantification of inter- and intra-individual variability…
Read moreCombining aggregate data and individual patient/subject data in model-based meta-analysis: An illustrative case study of tofacitinib in rheumatoid arthritis patients
Thursday 7 May, 2026
Introduction: Model-based meta-analysis (MBMA) is widely used to integrate aggregate data (AD) from randomized controlled trials (RCTs) within a pharmacologically…
Read moreMechanistic lumping of linear PBPK models
Thursday 7 May, 2026
OBJECTIVES Physiologically-based pharmacokinetic (PBPK) models predict blood and tissue concentrations through a complex physiological parametrization and compartmentalization. Proper lumping allows…
Read moreBenchmarking a Mechanistic Immunogenicity Framework: Aligning Sequence-Based Epitope Predictions with Clinical Observations
Thursday 7 May, 2026
Objective: Immunogenicity prediction is a critical component of monoclonal antibody (mAb) development. The emergence of anti-drug antibodies (ADA) remains a…
Read moreA population covariate modeling framework for IMPRES-M, the impulse-response modeling for population PK analysis based on P-splines
Thursday 7 May, 2026
Introduction/Objective: IMPRESM is a modeling tool for PK profile estimation and simulation, based on semi-parametric smoothing using P-splines and an…
Read moreBEYOND EMPIRICAL BIOAVAILABILITY SCALING: A MECHANISTIC MODEL INCORPORATING PRE- AND POST-SYSTEMIC SATURABLE PROCESSES TO CHARACTERIZE NON-LINEAR PK OF ORALLY ADMINISTERED SMALL MOLECULES
Thursday 7 May, 2026
Introduction: Non-linear pharmacokinetics (PK) of orally administered small molecules is frequently addressed through empirical model adaptations such as dose-dependent bioavailability…
Read moreModeling the stochasticity of bacterial resistance emergence to bacteriophages
Thursday 7 May, 2026
Objectives: Drug resistance may emerge through pressure exerted by antimicrobial treatments [1], which sometimes lead to acquisition of resistance and…
Read moreAccelerating Gold Standard Evolution in Pharmacometrics: A Framework for Cross-Study Benchmarking of Covariate Modeling Methods
Thursday 7 May, 2026
Objectives For the past few years, pharma industries have been working to shorten development timelines. In 2026, Sanofi aims at…
Read moreTHE TOP-DOWN PBFTPK MODELS VIS A VIS THE BOTTOM-UP PBPK MODELS IN EARLY DRUG DEVELOPMENT
Thursday 7 May, 2026
Introduction: The introduction of Finite Absorption Time (F.A.T.) [1,2] concept led to the development of Physiologically Based Finite Time Pharmacokinetic…
Read more